Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief - Featured image
Sleep Health

Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief

Obstructive sleep apnea (OSA) affects millions, disrupting sleep and impacting overall health. A recent study explores the effectiveness of hypoglossal nerve stimulation as a promising treatment option for those who haven't found relief with traditional methods.

Shotlee·October 22, 2025·Updated Jan 27, 2026·3 min read
Share:

Contents

  1. 01Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief
  2. 02Practical Takeaways
  3. 03What is Hypoglossal Nerve Stimulation?
  4. 04Key Findings from the OSPREY Trial
  5. 05Who Might Benefit from Hypoglossal Nerve Stimulation?
  6. 06The Future of Sleep Apnea Treatment
  7. 07Tracking Your Sleep Health
Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief

Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief

Obstructive sleep apnea (OSA) is a common condition where breathing repeatedly stops and starts during sleep. This can lead to fragmented sleep, daytime sleepiness, and increased risk of cardiovascular issues. While continuous positive airway pressure (CPAP) is a common treatment, it's not always well-tolerated. Now, a new approach called hypoglossal nerve stimulation is offering a promising alternative.

What is Hypoglossal Nerve Stimulation?

Hypoglossal nerve stimulation involves implanting a small device that stimulates the hypoglossal nerve, which controls tongue movement. By stimulating this nerve, the tongue is kept from collapsing into the airway during sleep, thus preventing apneas (pauses in breathing). Think of it as a tiny nudge that keeps your airway open while you sleep.

A recent study, the OSPREY trial, presented at the CHEST annual meeting, explored the effectiveness of a proximal hypoglossal nerve stimulation device. The results are encouraging, showing a significant reduction in sleep apnea events among participants.

Key Findings from the OSPREY Trial

The OSPREY trial demonstrated a clinically meaningful improvement in sleep apnea events with the aura6000 device. Here are some key highlights:

  • The Apnea-Hypopnea Index (AHI) response rate improved by 44.7 percentage points compared to the control group.
  • 65% response rate after 12 months.
  • A 68% reduction in both AHI and oxygen desaturation events per hour.
  • Patient-reported outcomes for daytime sleepiness and sleep quality improved.

These findings, combined with previous research like the THN3 trial, provide strong evidence for the effectiveness of hypoglossal nerve stimulation in treating OSA.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Who Might Benefit from Hypoglossal Nerve Stimulation?

Hypoglossal nerve stimulation may be a suitable option for individuals with moderate to severe OSA who:

  • Have failed or are unwilling to use CPAP therapy.
  • Have a body mass index (BMI) under 35.
  • Meet specific criteria determined by a sleep specialist.

Interestingly, some experts are exploring the potential of combining hypoglossal nerve stimulation with other treatments, such as weight loss medications like tirzepatide (Zepbound). This combination approach could potentially optimize treatment outcomes for individuals with OSA.

The Future of Sleep Apnea Treatment

The development of hypoglossal nerve stimulation represents a significant advancement in sleep apnea treatment. The OSPREY trial results have led to FDA submission of the aura6000 system, potentially expanding the treatment options available for those with OSA. As Dr. Nathan Nowalk noted, we're entering a new era where various treatments can be combined for a personalized approach.

Tracking Your Sleep Health

Understanding your sleep patterns and the effectiveness of any treatment is crucial. Tools like Shotlee can help you track your sleep quality, heart rate, and other vital signs, providing valuable data to share with your healthcare provider. By monitoring your progress, you can work with your doctor to optimize your sleep apnea treatment and improve your overall well-being.

Practical Takeaways

  • Hypoglossal nerve stimulation is an effective alternative to CPAP for many.
  • Consult with a sleep specialist to determine if you're a candidate.
  • Consider tracking your sleep data to monitor treatment effectiveness.

Hypoglossal nerve stimulation offers a promising solution for those struggling with sleep apnea. By keeping the airway open during sleep, this innovative treatment can significantly improve sleep quality and overall health.

Original source: MedPage Today

View original article →
#GLP-1#semaglutide#peptide therapy#weight loss#health tracking#wellness#Ozempic#Wegovy#Mounjaro#BPC-157#longevity#metabolic health#sleep apnea#hypoglossal nerve stimulation#OSA
  1. Home
  2. Blog
  3. Hypoglossal Nerve Stimulation: A New Hope for Sleep Apnea Relief

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community